In recent years, the quietly emerged Lao Big Bear version of Sotorasib, an affordable alternative to this targeted therapy for refractory KRAS G12C mutations, has gradually entered clinical view, and its real-world performance in efficacy and safety has garnered significant attention.
What are the purchasing channels for Lao Big Bear version of Sotorasib?
The Lao Big Bear version of Sotorasib is available in a specification of 120mg*56 tablets/box. For specific purchasing methods, it is recommended that you add professional customer service for detailed consultation.
Recommendations for the use of Sotorasib in pregnant, lactating, pediatric, and elderly patients
Regarding the use of Sotorasib in special populations, the following guiding principles should be followed. For pregnant women: There are no clinical data on the use of Sotorasib in pregnant women. Animal reproductive toxicity studies showed that in rat and rabbit embryo-fetal development experiments, oral administration of Sotorasib at doses up to the equivalent of the clinical recommended dose of 960 mg did not cause teratogenic or embryolethal effects. However, the background risk of major birth defects and miscarriage in clinically recognized pregnancies in the general U.S. population is 2%-4% and 15%-20%, respectively, so caution is still required. Women of childbearing potential are advised to take effective contraceptive measures during treatment. For lactating women: It is unknown whether Sotorasib or its metabolites are excreted into human milk, nor is it possible to determine the effect on breastfed infants. Due to the potential for serious adverse reactions in breastfed children, women are advised to discontinue breastfeeding during treatment with Sotorasib and for 1 week after the last dose. For pediatric patients: The safety and efficacy of Sotorasib in children have not been established, so it is not recommended for use in the pediatric population. For elderly patients: In the CodeBreaK 100 study, among 357 patients with various tumor types who received Sotorasib 960 mg orally once daily, 46% were aged 65 years and older, and 10% were aged 75 years and older. Comparative analysis showed no significant differences in overall safety or effectiveness between elderly and younger patients. This means that no age-based starting dose adjustment is needed for elderly patients, but close monitoring of liver and kidney function and concomitant medications is still required.
Warnings, precautions, and common adverse reactions of Sotorasib
During treatment with Sotorasib, two serious adverse reaction risks must be monitored. First is hepatotoxicity: Sotorasib can cause abnormal liver function indices, including elevated transaminases (ALT, AST) and total bilirubin. Therefore, liver function must be tested before starting treatment, then monitored every 3 weeks during the first 3 months of treatment, and monthly thereafter, or more frequently as clinically indicated. If signs of elevated transaminases and/or bilirubin occur, monitor more frequently. Based on the severity of the adverse reaction, the doctor may recommend withholding the dose, reducing the dose, or permanently discontinuing Sotorasib. Patients should contact their doctor immediately if they experience yellowing of the skin or whites of the eyes (jaundice), "tea-colored" urine, light-colored stools, weakness, vomiting, loss of appetite, bruising, or right upper abdominal pain. Second is interstitial lung disease (ILD)/pneumonitis: Sotorasib can cause lung inflammation, which can be fatal in severe cases. Patients should be closely monitored for new or worsening respiratory symptoms such as dyspnea, cough, fever, etc. If ILD/pneumonitis is suspected, Sotorasib should be discontinued immediately. In addition to the above serious side effects, the most common adverse reactions (with higher incidence) include: diarrhea, musculoskeletal pain, nausea, fatigue, cough, abnormal liver function tests, and certain blood test changes. Most adverse reactions can be managed with dose adjustment or symptomatic supportive care. There are no known contraindications. If dose reduction is required, it can first be reduced to 480 mg once daily (4 tablets); if still not tolerated, further reduce to 240 mg once daily (2 tablets). The minimum tolerated dose is 240 mg once daily; if still not tolerated, permanent discontinuation is required.
